ZIVO Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.4M | $-7.8M | $-8.7M | $-8.8M | $-9.1M | $-11.5M | $-14.6M | $-10.0M |
| Depreciation & Amortization | — | — | — | $0 | $0 | $0 | $0 | $18.8K |
| Depreciation | — | — | — | — | — | — | $0 | $18.8K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.5M | $89.5K | $-297.7K | $-104.6K | — | — | $87.5K | — |
| Net Cash from Operating Activities | $-4.3M | $-5.8M | $-7.1M | $-6.8M | $-2.6M | $-3.7M | $-5.0M | $-4.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $5.6M | $4.3M | $0 | $15.6M | $2.4M | $3.7M | $5.1M | $4.1M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |